All In Biotech

Drug Trial Radar · NCT06182085

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

Randomised, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

304

Actual

Start

Feb 15, 2024

Primary completion

Apr 15, 2026

Study completion Jul 2, 2026

Sponsor

Lead sponsor
PRInnovation GmbHIndustry
Sponsor type
Industry
Collaborators
Priavoid; Federal Agency for Disruptive Innovation - SPRIN-D; Julius Clinical
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour. The company PRInnovation is developing a new treatment for Alzheimer's disease, called PRI-002. It is thought that PRI-002 can cut the sticked substances back into small pieces. That would reduce the effects of Alzheimer's disease. In the current study the investigators examine whether PRI-002 is safe and effective in participants with mild cognitive impairment (MCI) or mild dementia due to AD.

Conditions

  • Mild Cognitive Impairment Due to Alzheimer's Disease
  • Alzheimer's Disease, Early Onset

Interventions

  • PRI-002Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of multiple doses of PRI-002 in subjects with MCI or mild dementia due to AD, based on incidence of drug-related adverse events (AEs).Time frame: Baseline to week 48.
  2. To evaluate the efficacy of multiple doses of PRI-002 in subjects with MCI or mild dementia due to AD, based on the Clinical Dementia Rating - Sum of Boxes (CDR-SB).Time frame: Baseline to week 48.

Locations

38 sites in 6 countries. Site status is shown where the registry gives one.

  • Neuro Health Centrum ltd.

    Brno, Czechia

  • NeuropsychiatrieHK, s.r.o.

    Hradec Králové, Czechia

  • A-Shine, s.r.o.

    Pilsen, Czechia

  • CLINTRIAL, s.r.o.

    Prague, Czechia

  • FORBELI s.r.o.

    Prague, Czechia

  • Neuropsychiatrie s.r.o.

    Prague, Czechia

  • INEP Medical s.r.o.

    Prague, Czechia

  • Uniklinik RWTH Aachen

    Aachen, Germany

  • Charité - Universitätsmedizin

    Berlin, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Magdeburg

    Magdeburg, Germany

  • ISPG - Institut für Studien zur Psychischen Gesundheit

    Mannheim, Germany

  • Technische Universität München

    München, Germany

  • Universitätsklinikum Münster - Klinik für Allgemeine Neurologie

    Münster, Germany

  • University Medical Center Rostock

    Rostock, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Ospedale Bellaria - IRCCS Istituto delle Scienze Neurologiche

    Bologna, Italy

  • ASST Spedali Civili di Brescia

    Brescia, Italy

  • Clinica Neurologica Dipartimento di Neuroscienze e Imaging (CAST)

    Chieti, Italy

  • IRCCS Ospedale San Raffaele

    Milan, Italy

  • Fondazione IRCCS.Istituto Neurologico Carlo Besta

    Milan, Italy

  • Ospedale Santa Maria della Misericordia

    Perugia, Italy

  • AOU Policlinico Umberto I

    Rome, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Rome, Italy

  • Brain Research Center Den Bosch B.V.

    's-Hertogenbosch, Netherlands

  • Brain Research Center Amsterdam B.V.

    Amsterdam, Netherlands

  • Brain Research Center Zwolle B.V.

    Zwolle, Netherlands

  • Revit Sp. z o.o., Podlaskie Centrum Psychogeriatrii

    Bialystok, Poland

  • Krakowska Akademia Neurologii Sp. z o.o., Centrum Neurologii Klinicznej

    Krakow, Poland

  • NeuroCor, ul. Medweciego 7/U12

    Krakow, Poland

  • Euromedis Sp. z o.o., Centrum Medyczne EUROMEDIS

    Szczecin, Poland

  • Neuroprotect Sp. z o.o., Centrum Medyczne NeuroProtect

    Warsaw, Poland

  • Wielospecjalistyczne Centrum Medyczne "Ibismed" s.c.

    Zabrze, Poland

  • Fundació ACE - Institut Català de Neurociències Aplicades

    Barcelona, Spain

  • Hospital Universitario Virgen Macarena,

    Seville, Spain

  • Hospital Universitario Doctor Peset

    Valencia, Spain

  • Hospital Viamed Montecanal

    Zaragoza, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    El Palmar, Murcia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.